Scynexis Stock Price, News & Analysis

SCYNEXIS (NASDAQ: SCYX) reported its full year 2024 financial results, highlighting key developments in its antifungal pipeline. The company's Phase 1 trial of SCY-247, initiated in December 2024, is progressing with results expected in Q3 2025. The company reported a net loss of $21.3 million ($0.44 per basic share) for 2024, compared to a net income of $67.0 million in 2023.

Financial highlights include revenue of $3.7 million from the GSK license agreement and a $10 million milestone payment from GSK. R&D expenses decreased by 14.6% to $26.4 million, while SG&A expenses reduced by 30.9% to $14.5 million. The company ended 2024 with cash, cash equivalents and investments of $75.1 million, projecting runway into Q3 2026.

SCYNEXIS anticipates restarting its Phase 3 MARIO study in invasive candidiasis in Q2 2025, pending FDA's lifting of the clinical hold.

SCYNEXIS (NASDAQ: SCYX) has initiated dosing in a Phase 1 trial of SCY-247, its second-generation triterpenoid antifungal candidate designed to combat severe invasive fungal infections. The trial is a randomized, double-blind, placebo-controlled study involving approximately 100 healthy subjects, focusing on single and multiple ascending doses of oral SCY-247.

The study's primary endpoint is safety and tolerability, with pharmacokinetics as the secondary endpoint. SCY-247 has shown promising results in preclinical models and demonstrates activity against fungi listed on the WHO fungal priority pathogen list. The development addresses growing concerns about drug resistance and increasing mortality rates in vulnerable populations affected by invasive fungal diseases.

SCYNEXIS reported Q3 2024 financial results, highlighting the receipt of a $10 million milestone payment from GSK following the delivery of clinical study reports for FURI, CARES, and NATURE trials. The company reported revenue of $0.7 million, R&D expenses of $8.1 million, and a net loss of $2.8 million. Cash position stands at $84.9 million, providing runway into Q3 2026. SCY-247, their second-generation antifungal, showed promising preclinical results, with Phase 1 trials expected to begin in Q4 2024. The Phase 3 MARIO trial in invasive candidiasis is anticipated to restart in Q1 2025.

SCYNEXIS (NASDAQ: SCYX), a biotechnology company focused on developing innovative medicines for difficult-to-treat and drug-resistant infections, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. David Angulo, M.D., President and CEO of SCYNEXIS, will engage in a fireside chat on Thursday, October 17, at 11:30 A.M. ET.

The event will be held virtually, and interested parties can sign up to view the presentation through a provided link. Additionally, one-on-one investor meetings will be available after the event upon request, which can be arranged through a separate link or by contacting a Maxim representative.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 in Los Angeles, CA from October 16-19, 2024. The company will present two sessions:

1. An oral presentation titled 'Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections' on October 17.

2. A poster presentation titled 'SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential' on October 18.

Both presentations will be delivered by David A. Angulo, M.D., President and CEO of SCYNEXIS.

SCYNEXIS (NASDAQ: SCYX), a biotechnology company focused on developing innovative medicines for difficult-to-treat and drug-resistant infections, has announced its participation in the H. C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 11, 2024, in New York City.

David Angulo, M.D., President and CEO of SCYNEXIS, will deliver a corporate presentation at 10:00 A.M. ET and will be available for one-on-one meetings with investors. Interested parties can request meetings through their H.C. Wainwright representative. The presentation will also be accessible via a live webcast, providing an opportunity for remote participation.

SCYNEXIS (NASDAQ: SCYX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Delivery of clinical study reports for FURI, CARES, and NATURE trials to GSK, triggering a $10 million milestone payment.

2. Progress on SCY-247's IND-enabling activities, with Phase 1 study planned for Q4 2024.

3. Q2 2024 ended with $83.7 million in cash, projecting a runway of over two years.

4. Q2 2024 financial results: $0.7 million revenue, $6.8 million R&D expense, $3.2 million SG&A expense, and a net loss of $14.5 million ($0.30 per share).

5. Ongoing work to restart the Phase 3 MARIO study in invasive candidiasis.

SCYNEXIS (NASDAQ: SCYX) announced it will receive a $10 million milestone payment from GSK, triggered by the delivery of final clinical study reports for the completed FURI, CARES, and NATURE trials. This payment is part of their exclusive license agreement for ibrexafungerp. Results from the FURI and CARES studies are positive and consistent with previous interim analyses. SCYNEXIS reiterates its cash runway of over two years and plans to advance SCY-247, its next-generation fungerp, into clinical trials later this year. The company has previously received $115 million from GSK and is eligible for up to $323 million more in potential payments, plus tiered royalties on ibrexafungerp sales.

SCYNEXIS, a biotechnology company, reported its first-quarter financial results for 2024, ending with $94.2 million in cash, with a projected cash runway of over two years. They continue to progress with SCY-247's development and anticipate a Phase I trial by 2024. The company is working on new manufacturing agreements due to clinical hold issues with ibrexafungerp and presented promising preclinical data for SCY-247 at a conference. SCYNEXIS expects to deliver study reports to GSK, triggering a $10 million milestone payment. Financially, revenue consisted of $1.4 million from a license agreement with GSK. Research and development expenses increased slightly, while SG&A expenses decreased. Net income for Q1 2024 was $0.4 million compared to a loss in the same period in 2023.